Results 261 to 270 of about 1,553,588 (375)

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

RNA therapeutics

RNA Biology, 2023
openaire   +4 more sources

Correction to "Abnormalities of Hippocampal Subfields in Individuals With Acute Carbon Monoxide Poisoning". [PDF]

CNS Neurosci Ther
europepmc   +1 more source

Coring of Intravitreal Medication Vial Stoppers: A Report From the Research in Safety and Therapeutics Committee of the American Society of Retina Specialists. [PDF]

J Vitreoretin Dis
Ali FS, Schneider EW, Arepalli S, Borkar D, Deaner JD, Jain N, London NJS, Suner IJ, Thomas AS, Vajzovic L, Vora RA, Witkin AJ.   +11 more
europepmc   +1 more source

ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee, Keyue Chen, Ryan Loke, Xiang Li, David Liubart, Golam T. Saffi, Jonathan T. S. Chow, Ché M. P. Melo, Lydia To, Leonardo Salmena   +9 more
wiley   +1 more source

Correction to "Protein Tyrosine Phosphatase 1B Contributes to Neuropathic Pain by Aggravating NF-κB and Glial Cells Activation-Mediated Neuroinflammation via Promoting Endoplasmic Reticulum Stress". [PDF]

CNS Neurosci Ther
europepmc   +1 more source

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML. [PDF]

J Clin Oncol
Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS.   +32 more
europepmc   +1 more source

Principles of Medicine: comprising General Pathology and Therapeutics, and a brief general View of Etiology, Nosology, Semeiology, Diagnosis, Prognosis, and Hygienics [PDF]

Charles J. B. Williams
openalex   +1 more source

Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes

Molecular Oncology, EarlyView.
Raphin‐1 reduces the survival of PED‐DHGG cells and enhances their radiation sensitivity through both PeIF2α‐dependent and PeIF2α‐independent mechanisms. Raphin‐1 sustains elevated levels of PeIF2α, contributing to its PeIF2α‐dependent effects. Additionally, raphin‐1 interacts with CReP to mediate a separate radiosensitizing pathway that operates ...
Karin Eytan, Moshe Leitner, Amos Toren, Shoshana Paglin, Michal Yalon   +4 more
wiley   +1 more source

A father's crusade in rare disease drug development: a case study of Elpida therapeutics and Melpida. [PDF]

Orphanet J Rare Dis
Portero D, Xu Q, Hussain A, Lo AW.
europepmc   +1 more source